Table of Contents
Exhibit 99.2
Table of Contents
(1Q of FY2006) - July 31, 2006
DAIICHISANKYO CO., LTD.
http://www.daiichisankyo.co.jp/
Table of Contents
1. Summary of Financial Statement
million yen
FY2005 | FY2006 | ||||||||||||||||||||||||||||||||
1Q* | progress (%) | 1st half | Full year | 1Q | progress (%) | 1st half Estimate | 1st half Estimate | Difference in May | Full year Estimate | Full year Estimate | |||||||||||||||||||||||
Change | <0.6> | <1.0> | <17.0> | <4.0> | <6.2> | <-6.6> | <-5.5> | ||||||||||||||||||||||||||
Net sales | 231,148 | 51.2 | % | 451,808 | 925,918 | 270,549 | 57.6 | % | 470,000 | 480,000 | 10,000 | 865,000 | 875,000 | ||||||||||||||||||||
Cost of sales | 72,511 | 51.3 | % | 141,296 | 290,735 | 73,589 | 55.2 | % | 133,400 | 136,800 | 3,400 | 234,200 | 237,600 | ||||||||||||||||||||
Cost of sales ratio | 31.4 | % | 31.3 | % | 31.4 | % | 27.2 | % | 28.4 | % | 28.5 | % | — | 27.1 | % | 27.2 | % | ||||||||||||||||
Selling, general and administrative expenses | 110,986 | 48.2 | % | 230,166 | 480,454 | 136,167 | 48.4 | % | 281,600 | 278,200 | (3,400 | ) | 522,800 | 519,400 | |||||||||||||||||||
SG&A ratio | 48.0 | % | 50.9 | % | 51.9 | % | 50.3 | % | 59.9 | % | 58.0 | % | — | 60.4 | % | 59.4 | % | ||||||||||||||||
Research and development expenses | 35,333 | 48.7 | % | 72,528 | 158,716 | 37,933 | 43.6 | % | 87,000 | 87,000 | 0 | 167,000 | 167,000 | ||||||||||||||||||||
R&D ratio | 15.3 | % | 16.1 | % | 17.1 | % | 14.0 | % | 18.5 | % | 18.1 | % | — | 19.3 | % | 19.1 | % | ||||||||||||||||
Change | <8.3> | <9.7> | <27.6> | <-31.5> | <-19.1> | <-30.2> | <-23.7> | ||||||||||||||||||||||||||
Operating income | 47,650 | 59.3 | % | 80,345 | 154,728 | 60,792 | 110.5 | % | 55,000 | 65,000 | 10,000 | 108,000 | 118,000 | ||||||||||||||||||||
/ Net sales | 20.6 | % | 17.8 | % | 16.7 | % | 22.5 | % | 11.7 | % | 13.5 | % | — | 12.5 | % | 13.5 | % | ||||||||||||||||
Change | <8.4> | <14.2> | <35.8> | <-27.4> | <-12.9> | <-28.0> | <-20.5> | ||||||||||||||||||||||||||
Ordinary income | 49,952 | 60.4 | % | 82,642 | 159,714 | 67,842 | 113.1 | % | 60,000 | 72,000 | 12,000 | 115,000 | 127,000 | ||||||||||||||||||||
/ Net sales | 21.6 | % | 18.3 | % | 17.2 | % | 25.1 | % | 12.8 | % | 15.0 | % | — | 13.3 | % | 14.5 | % | ||||||||||||||||
Change | <1.5> | <2.6> | <51.7> | <-23.2> | <-7.0> | <-46.4> | <-37.3> | ||||||||||||||||||||||||||
Net income | 31,642 | 64.0 | % | 49,450 | 87,692 | 48,001 | 126.3 | % | 38,000 | 46,000 | 8,000 | 47,000 | 55,000 | ||||||||||||||||||||
/ Net sales | 13.7 | % | 10.9 | % | 9.5 | % | 17.7 | % | 8.1 | % | 9.6 | % | 5.4 | % | 6.3 | % |
* | The amounts for the first quarter of fiscal 2005 are simple totals of the figures of the Sankyo Group and the Daiichi Pharmaceutical Group. |
• | The accounting period of DAIICHI SANKYO INC. (DSI) and Luitpold Pharmaceuticals Inc. (LPI), both of which are overseas subsidiaries of the DAIICHI SANKYO Group, is 15 months from January 2006 to March 2007. This is due to an adjustment made to the accounting period. Therefore, for these two companies, the accounting period for the first quarter is from January to June 2006. |
• | For the first half of fiscal 2006, an earnings forecast was made equaling half of the annual sales/profit for non-pharmaceutical operations operating as independent businesses outside of the DAIICHI SANKYO Group. |
• | In fiscal 2006, Zepharma Inc., Taiwan Sankyo Ltd. And Shanghai Sankyo Pharmaceuticals Ltd., were made consolidated subsidiaries of DAIICHI SANKYO CO., LTD. In the case of the share acquisition of Zepharma Inc., intangible assets and goodwill be amortized over a period of 10 years. |
2. Status in R&D Pipeline (Change from the announcement of May 2006)
Development Stage
Development Code Number | Before Change | After Change | Remarks | |||
DZ-697b | Japan:P-1 preparation | Japan:P-1 | anti-platelet agent | |||
CS-866AZ | Japan:P-2 | Japan:P-3 | antihypertensive drug (olmesartan/azelnidipine combination) | |||
CS-3030 | US/EU:P-1 preparation | US/EU:P-1 | oral factor Xa inhibitor | |||
CS-1008 | US/EU:P-1 preparation | US/EU:P-1 | anti-cancer drug(anti-DR5 antibody) |
1
Table of Contents
3. Main Prescription drug sales
million yen
FY2006 | ||||||||||||||||||||||||||||||
1Q | Change | Progress | 1st half issued in May | Change | 1st half Estimate | Change | Full year issued in May | Change | Full year Estimate | |||||||||||||||||||||
Japan | ||||||||||||||||||||||||||||||
Cardiovascular | ||||||||||||||||||||||||||||||
Mevalotin | 17,800 | -10.5 | % | 51.7 | % | 34,500 | -10.4 | % | 33,500 | (1,000 | ) | 68,200 | -9.3 | % | 67,200 | |||||||||||||||
Panaldine | 7,200 | -11.2 | % | 67.9 | % | 10,600 | -27.9 | % | 10,600 | ±0.0 | 19,700 | -30.4 | % | 19,700 | ||||||||||||||||
Artist | 5,200 | 5.0 | % | 56.5 | % | 9,200 | 1.1 | % | 9,200 | ±0.0 | 18,800 | 3.3 | % | 18,800 | ||||||||||||||||
Sunrythm | 3,200 | -3.5 | % | 57.1 | % | 5,600 | -6.7 | % | 5,600 | ±0.0 | 11,300 | -5.0 | % | 11,300 | ||||||||||||||||
Acecol | 2,200 | -12.4 | % | 61.1 | % | 3,600 | -25.0 | % | 3,600 | ±0.0 | 7,300 | -19.8 | % | 7,300 | ||||||||||||||||
Olmetec | 9,800 | 102.4 | % | 58.6 | % | 16,800 | 68.0 | % | 19,300 | 2,500 | 35,400 | 38.3 | % | 37,900 | ||||||||||||||||
Coversyl | 1,900 | -22.3 | % | 52.8 | % | 3,600 | -20.0 | % | 3,600 | ±0.0 | 7,100 | -15.5 | % | 7,100 | ||||||||||||||||
Hanp | 2,400 | 10.9 | % | 60.0 | % | 4,000 | 2.6 | % | 4,000 | ±0.0 | 9,200 | 7.0 | % | 9,200 | ||||||||||||||||
Calblock | 2,100 | 55.0 | % | 48.8 | % | 4,300 | 43.3 | % | 4,300 | ±0.0 | 9,200 | 43.8 | % | 9,200 | ||||||||||||||||
Livalo | 1,200 | 20.7 | % | 48.0 | % | 2,500 | 25.0 | % | 2,500 | ±0.0 | 5,600 | 36.6 | % | 5,600 | ||||||||||||||||
Glucose metabolic | ||||||||||||||||||||||||||||||
Fastic | 1,400 | -0.1 | % | 50.0 | % | 2,800 | 3.7 | % | 2,800 | ±0.0 | 5,700 | 7.5 | % | 5,700 | ||||||||||||||||
Infection | ||||||||||||||||||||||||||||||
Cravit | 11,600 | -13.2 | % | 53.0 | % | 21,900 | -7.2 | % | 21,900 | ±0.0 | 47,600 | -5.2 | % | 47,600 | ||||||||||||||||
Carbenin | 1,500 | -22.3 | % | 45.5 | % | 3,300 | -2.9 | % | 3,300 | ±0.0 | 6,400 | 1.6 | % | 6,400 | ||||||||||||||||
Banan | 1,100 | 1.6 | % | 52.4 | % | 2,100 | 5.0 | % | 2,100 | ±0.0 | 4,200 | -4.5 | % | 4,200 | ||||||||||||||||
Cancer | ||||||||||||||||||||||||||||||
Topotecin | 1,300 | 3.2 | % | 49.1 | % | 2,650 | 6.0 | % | 2,650 | ±0.0 | 5,550 | 15.6 | % | 5,550 | ||||||||||||||||
Immunological allergic | ||||||||||||||||||||||||||||||
Zyrtec | 2,900 | -16.7 | % | 56.3 | % | 5,150 | -8.0 | % | 5,150 | ±0.0 | 11,250 | -10.7 | % | 11,250 | ||||||||||||||||
Bone/Joint | ||||||||||||||||||||||||||||||
Loxonin | 8,000 | 6.9 | % | 56.7 | % | 14,100 | -1.4 | % | 14,100 | ±0.0 | 28,500 | -1.7 | % | 28,500 | ||||||||||||||||
Mobic | 2,900 | -0.9 | % | 52.7 | % | 5,500 | 1.9 | % | 5,500 | ±0.0 | 11,100 | 4.7 | % | 11,100 | ||||||||||||||||
Miltax | 1,400 | -9.2 | % | 48.3 | % | 2,900 | -6.5 | % | 2,900 | ±0.0 | 5,500 | -8.3 | % | 5,500 | ||||||||||||||||
Others | ||||||||||||||||||||||||||||||
Omnipaque | 8,400 | -12.2 | % | 54.2 | % | 15,500 | -13.9 | % | 15,500 | ±0.0 | 29,600 | -14.7 | % | 29,600 | ||||||||||||||||
Kremezin | 3,100 | -7.3 | % | 50.8 | % | 6,100 | -7.6 | % | 6,100 | ±0.0 | 12,400 | -4.6 | % | 12,400 | ||||||||||||||||
Zantac | 1,700 | -15.4 | % | 50.0 | % | 3,400 | -12.8 | % | 3,400 | ±0.0 | 6,600 | -10.8 | % | 6,600 | ||||||||||||||||
Omniscan | 1,400 | -4.7 | % | 53.8 | % | 2,600 | -7.1 | % | 2,600 | ±0.0 | 5,100 | -5.6 | % | 5,100 | ||||||||||||||||
Evoxac | 300 | 2.2 | % | 42.9 | % | 700 | ±0.0 | % | 700 | ±0.0 | 1,450 | 11.5 | % | 1,450 | ||||||||||||||||
Exports | ||||||||||||||||||||||||||||||
Pravastatin | 6,900 | -62.9 | % | 68.1 | % | 10,200 | -73.6 | % | 12,000 | 1,800 | 19,200 | -70.2 | % | 21,000 | ||||||||||||||||
Levofloxacin | 7,600 | -6.3 | % | 49.7 | % | 15,300 | 2.7 | % | 15,300 | ±0.0 | 30,300 | 2.7 | % | 30,300 | ||||||||||||||||
*Overseas | ||||||||||||||||||||||||||||||
DSI* | ||||||||||||||||||||||||||||||
Benicar/Benicar HCT** | 35,600 | — | 70.7 | % | 50,400 | 121.1 | % | 51,300 | 900 | 87,000 | 73.0 | % | 87,900 | |||||||||||||||||
(mil $) | (307 | ) | — | 70.3 | % | (438 | ) | 103.7 | % | (446 | ) | (8 | ) | (757 | ) | 66.0 | % | (765 | ) | |||||||||||
WelChol** | 8,700 | — | 71.0 | % | 12,300 | 66.2 | % | 12,300 | ±0.0 | 20,700 | 39.9 | % | 20,700 | |||||||||||||||||
(mil $) | (75 | ) | — | 70.6 | % | (107 | ) | 55.1 | % | (107 | ) | ±0.0 | (180 | ) | 34.3 | % | (180 | ) | ||||||||||||
Floxin Otic | 1,700 | 39.3 | % | 43.0 | % | 4,000 | 25.4 | % | 4,000 | ±0.0 | 7,800 | 26.5 | % | 7,800 | ||||||||||||||||
(mil $) | (14 | ) | 29.6 | % | 43.7 | % | (34 | ) | 17.2 | % | (34 | ) | ±0.0 | (67 | ) | 24.1 | % | (67 | ) | |||||||||||
Evoxac | 400 | 15.7 | % | 34.1 | % | 1,300 | 34.0 | % | 1,300 | ±0.0 | 2,700 | 12.3 | % | 2,700 | ||||||||||||||||
(mil $) | (3 | ) | 7.7 | % | 34.9 | % | (11 | ) | 25.0 | % | (11 | ) | ±0.0 | (23 | ) | 9.5 | % | (23 | ) | |||||||||||
LPI* | ||||||||||||||||||||||||||||||
Venofer** | 13,700 | — | 72.4 | % | 19,000 | 84.5 | % | 20,800 | 1,800 | 27,200 | 20.4 | % | 29,000 | |||||||||||||||||
(mil $) | (118 | ) | — | 71.6 | % | (166 | ) | 71.1 | % | (181 | ) | (15 | ) | (236 | ) | 15.1 | % | (251 | ) | |||||||||||
DSE* | ||||||||||||||||||||||||||||||
Olmetec | 5,200 | 44.8 | % | 55.1 | % | 9,500 | 31.9 | % | 9,500 | ±0.0 | 20,600 | 40.1 | % | 20,600 | ||||||||||||||||
(mil EURO) | (37 | ) | 40.9 | % | 53.1 | % | (70 | ) | 32.1 | % | (70 | ) | ±0.0 | (152 | ) | 42.1 | % | (152 | ) | |||||||||||
Mevalotin | 1,500 | 100.1 | % | 63.8 | % | 2,500 | 4.2 | % | 2,500 | ±0.0 | 5,200 | -5.5 | % | 5,200 | ||||||||||||||||
(mil EURO) | (11 | ) | 94.7 | % | 63.0 | % | (18 | ) | ±0.0 | % | (18 | ) | ±0.0 | (40 | ) | ±0.0 | % | (40 | ) |
* | The accounting period of DAIICHI SANKYO INC. (DSI) and Luitpold Pharmaceuticals Inc. (LPI), both of which are overseas subsidiaries of the DAIICHI SANKYO Group, is 15 months from January 2006 to March 2007. This is due to an adjustment made to the accounting period. Therefore, for these two companies, the accounting period for the first quarter is from January to June 2006. The accounting period of DAIICHI SANKYO EUROPE GmbH (DSE) is from January to March 2006. |
** | Sales of Benicar, WelChol and Venofer for 1Q shows 6 months sales. |
Reference(from January to March) : Benicar 15,600milion yen ($135mil), WelChol 3,900million yen($33mil), Venofer 6,800million yen($59mil)
*** | Sales of Floxin Otic and Evoxac shows 3 months sales. |
àExchange rate
1 $ = | 115.7 | 115 | 115 | 115 | ||||
1 EURO= | 140.7 | 135 | 135 | 135 |
2
Table of Contents
4. Consolidated sales of Global Products
million yen
FY2006 | ||||||||||||||||||||||||||
1Q | Change | Progress | 1st half issued in May | Change | 1st half Estimate | Full year issued in May | Change | Full year Estimate | ||||||||||||||||||
Olmesartan | 51,200 | — | 65.8 | % | 77,900 | 89.5 | % | 81,300 | 145,300 | 57.3 | % | 148,700 | 60.9 | % | ||||||||||||
Japan : Olmetec | 9,800 | 102.4 | % | 58.6 | % | 16,800 | 68.0 | % | 19,300 | 35,400 | 38.3 | % | 37,900 | 48.0 | % | |||||||||||
U.S.A: Benicar | 35,600 | * | — | 70.7 | % | 50,400 | 121.1 | % | 51,300 | 87,000 | 73.0 | % | 87,900 | 74.8 | % | |||||||||||
Europe: Olmetec | 5,200 | 44.8 | % | 55.1 | % | 9,500 | 31.9 | % | 9,500 | 20,600 | 40.1 | % | 20,600 | 40.1 | % | |||||||||||
Others | 600 | 152.1 | % | 43.9 | % | 1,200 | 9.1 | % | 1,200 | 2,300 | 27.8 | % | 2,300 | 27.8 | % | |||||||||||
Levofloxin | 23,500 | -7.9 | % | 51.8 | % | 45,600 | -2.1 | % | 45,800 | 95,900 | -1.7 | % | 95,900 | -1.7 | % | |||||||||||
Japan : Cravit | 11,600 | -13.2 | % | 53.3 | % | 21,900 | -7.2 | % | 21,900 | 47,600 | -5.2 | % | 47,600 | -5.2 | % | |||||||||||
Exports | 7,600 | -6.3 | % | 50.0 | % | 15,300 | 2.7 | % | 15,300 | 30,300 | 2.7 | % | 30,300 | 2.7 | % | |||||||||||
Royalty | 4,300 | 6.8 | % | 51.1 | % | 8,400 | 3.7 | % | 8,400 | 18,000 | 0.6 | % | 18,000 | 0.6 | % | |||||||||||
Pravastatin | 25,800 | -34.0 | % | 55.0 | % | 47,000 | -40.7 | % | 47,900 | 92,000 | -35.8 | % | 92,900 | -35.1 | % | |||||||||||
Japan: Mevalotin | 17,800 | -10.5 | % | 51.7 | % | 34,500 | -10.4 | % | 33,500 | 68,200 | -9.3 | % | 67,200 | -10.6 | % | |||||||||||
Europe | 1,500 | 100.1 | % | 63.8 | % | 2,500 | 4.2 | % | 2,500 | 5,200 | -5.5 | % | 5,200 | -5.5 | % | |||||||||||
Exports | 6,500 | -65.1 | % | 64.6 | % | 10,000 | -73.9 | % | 11,900 | 18,600 | -70.2 | % | 20,500 | -67.2 | % |
* | 6 months sales (from Jan. to Jun. 2006). |
million yen
FY2006 | ||||||||||||||||||
1Q | Change | Progress | 1st half issued in May | Change | Full year issued in May | Change | ||||||||||||
Total | 11,200 | — | +45.1 | % | 26,000 | 176.9 | % | 54,200 | 94.3 | % | ||||||||
LuLu series | 1,300 | 19.9 | % | 25.7 | % | 5,100 | 8.5 | % | 10,200 | 8.5 | % | |||||||
Shin-sankyo Ichoyaku series | 700 | 3.2 | % | 48.7 | % | 1,500 | -6.3 | % | 3,000 | -9.1 | % | |||||||
Karoyan series | 600 | 14.4 | % | 51.2 | % | 1,200 | 9.1 | % | 2,400 | 14.3 | % | |||||||
Regain series | 500 | -18.1 | % | 37.2 | % | 1,500 | 7.1 | % | 2,500 | 4.6 | % | |||||||
Patecs series | 600 | 21.3 | % | 59.5 | % | 1,000 | -9.1 | % | 2,300 | 15.0 | % | |||||||
Lamisil AT | 800 | -14.1 | % | 57.1 | % | 1,400 | 27.3 | % | 2,500 | -3.8 | % | |||||||
Gaster 10 | 1,000 | 4.7 | % | 48.4 | % | 2,000 | — | 4,200 | — | |||||||||
Precol | 300 | -3.5 | % | 25.6 | % | 1,000 | — | 2,500 | — | |||||||||
Cakonal | 200 | 20.4 | % | 27.5 | % | 800 | — | 2,000 | — | |||||||||
Makiron | 600 | -8.2 | % | 49.0 | % | 1,200 | — | 1,800 | — |
3
Table of Contents
6. Consolidated Segment information - Business
million yen
FY2005 | FY2006 | |||||||
1Q | 1st half | Full year | 1Q | |||||
Domestic | 112,796 | 208,266 | 431,401 | 117,172 | ||||
Overseas | 70,471 | 145,253 | 289,530 | 110,358 | ||||
OTC drugs | 6,462 | 14,794 | 27,900 | 11,221 | ||||
Pharmaceuticals | 198,498 | 385,415 | 784,666 | 247,567 | ||||
Other | 32,649 | 66,393 | 141,251 | 22,982 | ||||
Consolidated Sales | 231,148 | 451,808 | 925,918 | 270,549 | ||||
Pharmaceuticals | 48,860 | 77,651 | 148,114 | 59,410 | ||||
Other | 484 | 2,321 | 6,146 | 1,267 | ||||
Consolidated Operating income | 47,650 | 80,345 | 154,728 | 60,792 |
7. Consolidated Segment information - Area
million yen
FY2005 | FY2006 | |||||||||||||||
1Q | % | 1st half | Full year | 1Q | % | |||||||||||
Japan | 192,637 | 83.3 | % | 371,239 | 752,793 | 179,214 | 66.2 | % | ||||||||
North America | 25,093 | 10.9 | % | 53,741 | 116,061 | 71,068 | 26.3 | % | ||||||||
Europe | 10,705 | 4.6 | % | 21,345 | 45,473 | 16,301 | 6.0 | % | ||||||||
Other | 2,712 | 1.2 | % | 5,481 | 11,589 | 3,965 | 1.5 | % | ||||||||
Consolidated Sales | 231,148 | 100.0 | % | 451,808 | 925,918 | 270,549 | 100.0 | % | ||||||||
Japan | 42,008 | 69,124 | 130,249 | 51,057 | ||||||||||||
North America | 5,806 | 11,916 | 25,457 | 23,481 | ||||||||||||
Europe | (55 | ) | (1,924 | ) | (685 | ) | 4,773 | |||||||||
Other | 252 | 472 | 863 | 176 | ||||||||||||
Consolidated Operating income | 47,650 | 80,345 | 154,728 | 60,792 |
• | The accounting period of DAIICHI SANKYO INC. (DSI) and Luitpold Pharmaceuticals Inc. (LPI), both of which are overseas subsidiaries of the DAIICHI SANKYO Group, is 15 months from January 2006 to March 2007. This is due to an adjustment made to the accounting period. Therefore, for these two companies, the accounting period for the first quarter is from January to June 2006. |
• | In fiscal 2006, Zepharma Inc., Taiwan Sankyo Ltd. And Shanghai Sankyo Pharmaceuticals Ltd., were made consolidated subsidiaries of DAIICHI SANKYO CO., LTD. |
4
Table of Contents
Segment Information (Reference)
million yen
FY2006 | ||||||||||
1Q | 1st half Estimate issued in May | 1st half Estimate | Full year Estimate issued in May | Full year Estimate | ||||||
Pharmaceuticals | ||||||||||
Domestic (Sankyo, Daiichi Pharmaceuticals non-consolidated) | 117,172 | 202,400 | 203,900 | 414,500 | 416,000 | |||||
US | ||||||||||
Exports | 8,868 | 21,000 | 22,000 | 43,800 | 44,800 | |||||
DSI* | 47,265 | 69,700 | 70,600 | 121,700 | 122,600 | |||||
LPI** | 23,808 | 30,600 | 35,500 | 46,900 | 51,800 | |||||
Europe | ||||||||||
Exports | 9,589 | 12,900 | 14,000 | 22,900 | 24,000 | |||||
DSE*** | 15,878 | 25,800 | 25,800 | 49,600 | 49,600 | |||||
DAIICHI SANKYO HEALTHCARE CO., LTD. ZEPHARMA | 11,221 | 26,000 | 26,000 | 54,200 | 54,200 | |||||
Other Company(Total) | 13,766 | 25,600 | 26,200 | 53,400 | 54,000 | |||||
Other | 22,982 | 56,000 | 56,000 | 58,000 | 58,000 | |||||
Consolidated Sales | 270,549 | 470,000 | 480,000 | 865,000 | 875,000 |
* | Sales of Sales&Marketing Division. Accounting period is 15-month fiscal year (Jan. 2006 to Mar.2007). |
** | Accounting period is 15-month fiscal year (Jan. 2006 to Mar.2007). |
*** | Sales of Sales & Marketing Division. |
5